Fischer Medical Ventures Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2026 ,inter alia, to consider and approve The unaudited Standalone ....
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fischer Medical Ventures has informed BSE that its Board of Directors will meet on January 30, 2026 via video conferencing to consider and approve the unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Q3 FY26). The trading window for designated persons, their relatives, and other connected persons is already closed and will remain so until 48 hours after the results are declared. The filing is made under SEBI's Listing Obligations and Disclosure Requirements (Regulation 29) and is signed by the Company Secretary, Aravindkumar V.
No direct impact on shareholders from this notice alone. Investors should watch for the Q3 FY26 results on or after January 30, 2026 — actual earnings details, revenue growth, and margin performance will be known only once the results are announced.